Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab

J Eur Acad Dermatol Venereol. 2022 Jan:36 Suppl 1:53-58. doi: 10.1111/jdv.17658.

Abstract

It is well known that organ transplant recipients are prone to develop non-melanoma skin cancers, particularly cutaneous squamous cell carcinoma (cSCC). This is explained by the long-term use of immunosuppressants and thus the decrease of the immunosurveillance that protects from developing malignant tumours. Solid organ transplant recipients (SOTRs) are 65-250 times more likely to develop cSCC compared to the general population (Am J Transplant 2017; 17: 2509). Moreover, in these patients cSCCs follow a more aggressive course. Close follow-up and regular skin check-ups by a dermatologist are, therefore, crucial in the management of these patients. When detected early, cSCC can be easily and effectively treated by a simple excision. However, when advanced, outcomes are poor. Immune checkpoints inhibitors (ICIs) have been recently added to our arsenal and represent a breakthrough, having proved to be effective in achieving long-term responses. We, hereby, present two cases of difficult-to-treat cSCCs in renal transplanted patients.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Squamous Cell* / surgery
  • Humans
  • Kidney Transplantation* / adverse effects
  • Skin Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • cemiplimab